CD20单克隆抗体治疗自身免疫性溶血性贫血的进展

Progression of CD20 monoclonal antibody in the treatment of autoimmune hemolytic anemia

自身免疫性溶血性贫血(autoimmune hemolytic anemia,AIHA)是一种由红细胞自身抗体损伤红细胞导致其寿命缩短的自身免疫性疾病,由于免疫失耐受及免疫调节异常,B淋巴细胞功能亢进产生了红细胞自身抗体。抗CD20单克隆抗体通过减少B淋巴细胞治疗AIHA,是温抗体型AIHA的二线治疗药物和冷抗体型AIHA的一线治疗药物。目前抗CD20单克隆抗体治疗AIHA的最优剂量尚无定论,也无第2代及第3代抗CD20单克隆抗体治疗原发性AIHA的报道。

Autoimmune hemolytic anemia(AIHA)is an autoimmune disease in which the life span of red blood cells is shortened by red blood cell autoantibodies.Due to immune intolerance and abnormal immune regulation,the hyperfunction of B lymphocytes produces too many red blood cell autoantibodies.Anti-CD20 monoclonal antibody is a second-line drug for warm antibody AIHA and first-line drug for cold antibody AIHA by reducing B lymphocytes.At present,the optimal dose of anti-CD20 monoclonal antibody in the treatment of AIHA has not been determined.There are no reports on the treatment of primary AIHA with second-or third-generation anti-CD20 monoclonal antibodies.